Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1440-1746|30|11|1591-1595

ISSN： 0815-9319

Source： JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.30, Iss.11, 2015-11, pp. : 1591-1595

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hepatitis B vaccine in bowel disease

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 1, 2015-01 ,pp. : 92-98

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Azathioprine in inflammatory bowel disease, a safe alternative?

By Tanis A. A.  

Mediators of Inflammation, Vol. 7, Iss. 3, 1998-06 ,pp. : 141-144

Informa Healthcare

Access to resources Recommend Favorite

Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease

By Pasternak Björn   Svanström Henrik   Schmiegelow Kjeld   Jess Tine   Hviid Anders  

American Journal of Epidemiology, Vol. 177, Iss. 11, 2013-06 ,pp. : 1296-1305

Oxford University Press

Access to resources Recommend Favorite